It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

SNSE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 22.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Sensei Biotherapeutics Insider Trading History Chart

Sensei Biotherapeutics Share Price & Price History

^$0.51

▲ +0.0163 (3.27%)

As of 11/21/2024 10:30 AM ET

Days: 30 | 90 | 365

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Sensei Biotherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2023	John Celebi	CEO	Buy	500	$0.85	$425.00	111,311
6/1/2023	Apeiron Investment Group Ltd.	Major Shareholder	Sell	3,441,661	$1.58	$5,437,824.38
2/23/2023	Apeiron Investment Group Ltd.	Major Shareholder	Buy	2,200	$1.61	$3,542.00	2,485,923
3/2/2022	James Peyer	Director	Buy	1,203	$3.20	$3,849.60
3/1/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	2,458	$3.60	$8,848.80
2/28/2022	James Peyer	Director	Buy	42	$3.60	$151.20
2/24/2022	James Peyer	Director	Buy	15,000	$3.63	$54,450.00
2/23/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	2,500	$3.80	$9,500.00
2/18/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	15,000	$3.97	$59,550.00
2/17/2022	James Peyer	Director	Buy	4,949	$4.17	$20,637.33
2/16/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	2,551	$4.25	$10,841.75
2/14/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	10,000	$4.18	$41,800.00
2/11/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	12,500	$4.40	$55,000.00
2/10/2022	James Peyer	Director	Buy	5,000	$4.58	$22,900.00
2/8/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	10,000	$4.33	$43,300.00
2/4/2022	James Peyer	Director	Buy	2,500	$4.45	$11,125.00
2/3/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	17,500	$4.65	$81,375.00
1/28/2022	James Peyer	Director	Buy	8,900	$4.22	$37,558.00
1/27/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	6,100	$4.31	$26,291.00
1/26/2022	James Peyer	Director	Buy	29,900	$4.62	$138,138.00
1/25/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	20,100	$4.86	$97,686.00
1/24/2022	James Peyer	Director	Buy	22,707	$4.69	$106,495.83
1/21/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	24,703	$4.94	$122,032.82
1/20/2022	James Peyer	Director	Buy	20,000	$5.17	$103,400.00
1/19/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	10,244	$4.97	$50,912.68
1/18/2022	James Peyer	Director	Buy	10,000	$5.08	$50,800.00
1/14/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	6,219	$4.99	$31,032.81
1/13/2022	James Peyer	Director	Buy	19,953	$5.13	$102,358.89
1/12/2022	Cambrian Biopharma Inc	Major Shareholder	Buy	9,202	$5.22	$48,034.44
1/11/2022	James Peyer	Director	Buy	10,845	$5.18	$56,177.10
12/29/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	69,000	$4.98	$343,620.00
12/28/2021	James Peyer	Director	Buy	11,288	$5.28	$59,600.64
12/27/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	3,712	$5.30	$19,673.60
12/23/2021	James Peyer	Director	Buy	11,000	$5.27	$57,970.00
12/17/2021	James Peyer	Director	Buy	117	$5.29	$618.93
12/16/2021	Cambrian Biopharma Inc	Major Shareholder	Buy	10,925	$5.25	$57,356.25
12/9/2021	Thomas G. Ricks	Director	Buy	20,000	$6.62	$132,400.00

Breaking News: Tesla headed to $500…

From WealthPress | Ad

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

SEC Filings (Institutional Ownership Changes) for Sensei Biotherapeutics (NASDAQ:SNSE)

10.50% of Sensei Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Sensei Biotherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	National Bank of Canada FI	45,575	$27K	0.0%	+355.8%	0.181%
11/14/2023	Newtyn Management LLC	1,800,000	$1.35M	0.3%	-1.5%	7.200%
11/14/2022	RA Capital Management L.P.	683,529	$1.06M	0.0%	-5.5%	2.225%
7/22/2022	Truist Financial Corp	19,934	$45K	0.0%	-60.5%	0.065%
5/3/2022	Leo Brokerage LLC	14,845	$34K	0.0%	N/A	0.048%
11/16/2021	Millennium Management LLC	258,659	$2.72M	0.0%	N/A	0.846%
11/16/2021	Moore Capital Management LP	49,341	$0.52M	0.0%	-61.3%	0.161%
11/12/2021	Tao Capital Management LP	32,784	$0.35M	0.1%	N/A	0.107%
11/12/2021	The Manufacturers Life Insurance Company	13,478	$0.14M	0.0%	N/A	0.044%
11/12/2021	Geode Capital Management LLC	273,978	$2.88M	0.0%	+93.2%	0.896%
11/10/2021	Citigroup Inc.	2,409	$25K	0.0%	+565.5%	0.008%
11/9/2021	BlackRock Inc.	1,000,322	$10.52M	0.0%	+175.2%	3.270%
11/5/2021	Truist Financial Corp	70,374	$0.74M	0.0%	N/A	0.230%
11/4/2021	Deutsche Bank AG	12,021	$0.13M	0.0%	+158.3%	0.039%
11/1/2021	SG Americas Securities LLC	12,614	$0.13M	0.0%	N/A	0.041%
10/13/2021	BFT Financial Group LLC	14,845	$0.16M	0.0%	N/A	0.049%
8/17/2021	Citadel Advisors LLC	283,667	$2.77M	0.0%	-59.0%	0.927%
8/16/2021	Alyeska Investment Group L.P.	40,000	$0.39M	0.0%	N/A	0.131%
8/16/2021	Tudor Investment Corp Et Al	28,111	$0.27M	0.0%	-75.2%	0.092%
8/16/2021	Charles Schwab Investment Management Inc.	54,965	$0.54M	0.0%	+18.9%	0.180%
8/16/2021	State Street Corp	100,000	$0.98M	0.0%	+70.2%	0.327%
8/13/2021	Formula Growth Ltd.	100,000	$0.98M	0.1%	+77.7%	0.327%
8/13/2021	Northern Trust Corp	75,011	$0.73M	0.0%	-8.5%	0.245%
8/13/2021	Geode Capital Management LLC	141,809	$1.38M	0.0%	+20.8%	0.464%
8/13/2021	Vanguard Group Inc.	387,753	$3.78M	0.0%	+19.4%	1.268%
8/12/2021	JPMorgan Chase & Co.	179,078	$1.75M	0.0%	+15.1%	0.585%
8/11/2021	Bank of New York Mellon Corp	18,431	$0.18M	0.0%	+31.1%	0.060%
8/11/2021	BlackRock Inc.	363,466	$3.55M	0.0%	+9.2%	1.188%
8/11/2021	Deutsche Bank AG	4,653	$45K	0.0%	-73.3%	0.015%
8/2/2021	New York State Common Retirement Fund	5,396	$53K	0.0%	+37.2%	0.018%
5/27/2021	Davidson Kempner Capital Management LP	26,000	$0.38M	0.0%	N/A	0.085%
5/21/2021	Citadel Advisors LLC	692,537	$10.06M	0.0%	N/A	2.264%
5/18/2021	Zimmer Partners LP	46,000	$0.67M	0.0%	N/A	0.150%
5/18/2021	Tudor Investment Corp Et Al	113,353	$1.65M	0.0%	N/A	0.371%
5/18/2021	Duquesne Family Office LLC	100,000	$1.45M	0.0%	N/A	0.327%
5/18/2021	Davidson Kempner Capital Management LP	26,000	$0.38M	0.0%	N/A	0.085%
5/18/2021	Citadel Advisors LLC	692,537	$10.06M	0.0%	N/A	2.264%
5/18/2021	Falcon Edge Capital LP	213,658	$3.10M	0.2%	N/A	0.699%
5/18/2021	California State Teachers Retirement System	11,494	$0.17M	0.0%	N/A	0.038%
5/17/2021	Deerfield Management Company L.P. Series C	375,000	$5.45M	0.1%	N/A	1.226%
5/17/2021	Nuveen Asset Management LLC	12,340	$0.18M	0.0%	N/A	0.040%
5/13/2021	Bank of New York Mellon Corp	14,062	$0.21M	0.0%	N/A	0.046%
5/12/2021	Serengeti Asset Management LP	20,000	$0.29M	0.1%	N/A	0.065%
5/12/2021	Northern Trust Corp	81,947	$1.19M	0.0%	N/A	0.268%
5/12/2021	Geode Capital Management LLC	117,406	$1.71M	0.0%	N/A	0.384%
5/12/2021	Pura Vida Investments LLC	67,357	$0.94M	0.0%	N/A	0.220%
5/12/2021	JPMorgan Chase & Co.	155,647	$2.26M	0.0%	N/A	0.509%
5/12/2021	UBS Group AG	2,099	$31K	0.0%	N/A	0.007%
5/11/2021	New York State Common Retirement Fund	3,934	$57K	0.0%	N/A	0.013%
5/7/2021	BlackRock Inc.	332,700	$4.83M	0.0%	N/A	1.088%
5/7/2021	American International Group Inc.	4,441	$65K	0.0%	N/A	0.015%

Data available starting January 2016

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Today's Range

Now: $0.51

$0.51

50 Day Range

MA: $0.52

$0.42

$0.78

52 Week Range

Now: $0.51

$0.38

$1.94

Volume

11,513 shs

Average Volume

196,247 shs

Market Capitalization

$12.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.06

Who are the company insiders with the largest holdings of Sensei Biotherapeutics?: Sensei Biotherapeutics' top insider shareholders include:
Apeiron Investment Group Ltd (Major Shareholder)
John Celebi (CEO)
Learn More about top insider investors at Sensei Biotherapeutics.
Who are the major institutional investors of Sensei Biotherapeutics?: Sensei Biotherapeutics' top institutional shareholders include:
National Bank of Canada FI — 0.18%
Learn More about top institutional investors of Sensei Biotherapeutics stock.
Which major investors are buying Sensei Biotherapeutics stock?: Within the last quarter, SNSE stock was purchased by institutional investors including:
National Bank of Canada FI
Within the previous year, these company insiders have bought Sensei Biotherapeutics stock:
Apeiron Investment Group Ltd (Major Shareholder)
John Celebi (CEO)
Learn More investors buying Sensei Biotherapeutics stock.

Tesla Execs are Freaking Out

From Angel Publishing | Ad

Click here to get the details.